06 Jun

GoodGut abre una ronda de financiación en Capital Cell para ultimar su test de cáncer colorrectal

GoodGut abre una ronda de financiación en Capital Cell para ultimar su test de cáncer colorrectal

INVIERTE

GoodGut celebra su quinto aniversario con varios hitos empresariales, médicos y científicos logrados. Con la mirada puesta en finalizar la validación clínica del RAID-CRC, el primer test no invasivo para el diagnóstico precoz del cáncer colorrectal a partir de la microbiota intestinal, la empresa biotecnológica acaba de poner en marcha una ampliación de capital de 400.000 euros. Los pequeños inversores, médicos, pacientes y sociedad en general pueden acceder con tickets a partir de 500 euros en la plataforma especializada en salud Capital Cell.

Desde su creación en 2014, de la mano de Jesús García-Gil, Xavier Aldeguer y Mariona Serra, GoodGut ha conseguido tener tres productos con marcado CE: RAID-Dx, test diagnóstico no invasivo para el Síndrome del Intestino Irritable (SII); RAID-Monitor, test no invasivo para monitorizar la actividad de la EII (EII), y TestUrGut, un test no invasivo que permite conocer la microbiota intestinal.

También ha obtenido la licencia de fabricante de producto de diagnóstico in vitro otorgada por la Agencia Española del Medicamento y Producto Sanitario (AEMPS) y la certificación del sistema de calidad ISO 13485.

Recientemente, GoodGut ha firmado un acuerdo de distribución con Palex Medical, empresa líder en productos de diagnóstico in vitro en enfermedades digestivas en España y Portugal.

Mariona Serra, CEO de la compañía, explica que “damos la oportunidad a sumarse a este impulso final que nos permitirá entrar en el valioso mercado del producto de diagnóstico in vitro y hacer que la detección precoz de las enfermedades digestivas esté al alcance de todos“.

A lo largo de estos años, GoodGut ha levantado financiación por más de 2,5 millones de euros de Caixa Capital Risc, el Instituto Catalán de Finanzas, así como la Comisión Europea y el Ministerio de Economía y Competitividad español a través de programas competitivos del H2020 y RETOS por la innovación.

23 Apr

GoodGut signs an agreement with Palex to launch first non-invasive diagnostic tests for IBS and IBD

GoodGut signs an agreement with Palex to launch first non-invasive diagnostic tests for IBS and IBD

GoodGut has signed an agreement with Palex Medical to start selling its new non-invasive diagnostic tests RAID-Dx for irritable bowel syndrome (IBS) and RAID-Monitor for inflammatory bowel disease (IBD) in Spain.

These are the first products developed by GoodGut to reach the patient after ten years of R&D and clinical validation with internationally prestigious digestive system researchers and gastroenterologists. They are all based on patented technology that detects a specific strain of bacteria for each of the pathologies in a faeces sample.

The system provides significant benefits for the medical community and patients. RAID-Dx is the first tool that can be used for a fast and reliable diagnosis of IBS, which until now could only be diagnosed by excluding other pathologies, and also offers a differential diagnosis from IBD. RAID-Monitor meanwhile can be used to detect IBD and carry out monitoring that significantly improves patients’ quality of life.

GoodGut was created in 2014 to introduce a new global paradigm into the clinical standards for digestive diseases. “This agreement with a leading firm like Palex Medical and starting to sell our products is a real step forward“, says Mariona Serra, co-founder and CEO of GoodGut. “We are proud that knowledge generated in academia with the doctors Xavier Aldeguer and Jesús Gil has turned into new medical solutions for society”, she tells us.

“We feel very fortunate to have been able to work with GoodGut in making this innovative technology offering clinicians new tools for improving patients’ quality of life accessible to clinical laboratories and gastroenterologists”, says Montse Carenys, director of the In Vitro Diagnosis and Oncology Division at Palex Medical.

Palex Medical is Spain’s leading company in the field of diagnosing and monitoring IBD. As a result of the agreement reached with GoodGut, Palex Medical has been able to include diagnostic tools that are unique to the market in its portfolio.

Almost half of all Spaniards suffer from a digestive pathology according to the Spanish Digestive System Foundation. To prevent the occurrence of diseases of this type from increasing, it is important to encourage the population to adopt healthy habits and to develop new medical solutions for prevention and early stage diagnosis. IBS is one of the ten most difficult diseases to identify according to the Fleming list and in the case of IBD it is estimated that up to 45% of patients wait for over a year for diagnosis, and 17% for over five years.

Currently GoodGut has five products in development in the pipeline (four non-invasive diagnostic tests and a prebiotic).

Photo: From left to right, Montse Carenys (Palex), Xavier Vengochea (Palex), Mariona Serra (GoodGut), Jaume Clarina (Palex), Juan Manuel Garcia (Palex) and Dr Xavier Aldeguer (GoodGut).

In the media:

20 Mar

2019 InSiGHT Meeting

2019 InSiGHT Meeting

The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) and the New Zealand Society of Gastroenterology (NZSG) are organising the 2019 InSiGHT Meeting, to be held in New Zealand for the first time from 20 to 23 March.

Dr Gabriel Capella, director of the Hereditary Cancer Program at the Catalan Institute of Oncology (ICO) is one of this year’s guest speakers. Their research focuses on studying the genetic basis of gastrointestinal cancer, with a particular interest in hereditary colorectal cancer. He took part in the Research Challenges Programme awarded to GoodGut by the Spanish Ministry of Economy and Competitiveness in 2016. After three years of study, the results will be presented at the 2019 InSiGHT Meeting on 21 March under the title RAID-LS: A non-invasive tool based on faecal bacterial signature for Lynch Syndrome surveillance.

Lynch syndrome is an inherited condition that increases risk of colon cancer, endometrial cancer and several other cancers. Doctors estimate that around 3 out of every 100 colon cancers or endometrial cancers are caused this syndrome.

Date: 20-23 March, 2019
Place: Skycity Auckland Convention Centre (New Zealand)

More information

06 Mar

14th Congress of the European Crohn’s and Colitis Organisation

14th Congress of the European Crohn’s and Colitis Organisation

GoodGut will participate at the 14th Congress of the European Crohn’s and Colitis Organisation (ECCO Congress), the major inflamatory bowel disease (IBD) meeting in the world attracting over 6,500 participants, will be held in Copenhagen from 6 to 9 March 2019. The ECCO Congress theme for this year is suitably titled Research drives clinical care where personalised approaches for individual patient treatments will take center stage.

A total of 1,228 abstracts have been submitted to this year’s Congress. A panel of expert reviewers have evaluated and selected the strongest and most scientifically relevant abstracts for presentation. One of them is the RAID-Monitor of GoodGut.

Joan Amoedo, researcher at GoodGut, will present the poster RAID-Monitor: a new non-invasive method to determine endoscopic activity in IBD in the section Clinical, diagnosis and outcome. RAID-Monitor is an accurate bacterial-based biomarker that correlates well with endoscopic activity in both CD and UC patients. Sensitivity and specificity obtained with our method are the highest among the techniques compared. Therefore, RAID-Monitor is a good candidate to become the non-invasive method of choice to monitor the endoscopic activity in both diseases.

Date: 6-9 March, 2019
Place: Bella Center (Copenhagen)

More information

24 Jan

XXVIII Congrés de la Societat Catalana de Digestologia

XXVIII Congrés de la Societat Catalana de Digestologia

L’equip científic de GoodGut presentarà quatre pòsters al XXVIII Congrés de la Societat Catalana de Digestologia, que se celebrarà del 24 al 26 de gener al Palau Firal i de Congressos de Tarragona:

  • L’ús d’una nova signatura bacteriana fecal per a la personalització del seguiment del síndrome de Lynch a càrrec de Marta Malagón
  • Compensació de l’activitat enzimàtica de pacients amb pancreatitis crònica per la microbiota intestinal a càrrec de Lia Oliver
  • RAID-Dx: El primer test per al diagnòstic de la Síndrome de l’Intestí Irritable basat en la microbiota fecal a càrrec de Joan Amoedo
  • Estudi de l’efecte de la dieta en la microbiota intestinal en participants del programa de cribratge del càncer colorectal a càrrec de Marta Malagón

Data: del 24 al 26 de gener de 2019
Lloc: Palau de Congressos de Tarragona

Més informació

 

24 Jan

Interclúster “Nutrició i salut: descobrint nous reptes”

Interclúster “Nutrició i salut: descobrint nous reptes”

GoodGut participarà a l’Interclúster Nutrició i salut: descobrint nous reptes que organitzen CataloniaBio & HealthTech, el Clúster de Salut Mental i el Food Nutrition Cluster, el dia 24 de febrer a Sant Boi de Llobregat, amb l’objectiu de debatre les necessitats no cobertes al sector i poder aportar el seu coneixement com a empresa dedicada a la recerca i desenvolupament de sistemes no invasius de suport al diagnòstic i al tractament de malalties digestives basats en la microbiota intestinal.

Data: 24 de febrer de 2019
Lloc: Palau Marianao · Passeig President Josep Terradellas, 25 · Sant Boi de Llobregat

Més informació

06 Dec

Mariona Serra receives the Fidem award for innovation

Mariona Serra receives the Fidem award for innovation

The co-founder and CEO of GoodGut, Mariona Serra, was honoured with the Fidem 2018 award for innovation at a gala held on 29 November in CaixaFòrum Barcelona. Serra received the award from the Catalan Minister of the Presidency, Elsa Artadi, who took part in the event alongside the Minister of Enterprise and Knowledge, Àngels Chacón.

For the last 21 years, the International Foundation for Women Entrepreneurs (Fidem) has through this award recognised successes and initiatives by women who, through good management of their businesses, contribute to economic and social development. “These women are pioneers in their speciality and will become a reference for future generations” explained Joana Amat, president of Fidem.

“I was delighted to receive this recognition as women are well represented within GoodGut, not only in management but also the scientific team. It was a very exciting award. It is important to continue to raise the profile of women in the world of business and entrepreneurship” said Mariona Serra.

Fidem also recognised the talent of seven other businesswomen, entrepreneurs and executives: Therese Jamaa, General Manager of GSMA Mobile World Capital; Angie Rosales, director of Pallapupas; Inka Guixà, Chief Executive of La Farga; Àngels Roqueta, founding partner of Compas Private Equity; Aina Juliol, CEO of PGI Engineering; Emília Vila, co-founder and CEO of Agroptima, and Mireia Banega, founder of Eya Bach.

News in the press:

 

05 Dec

Biocat Report 2017 Presentation

Biocat Report 2017 Presentation

GoodGut will participate at the presentation of the Biocat Report 2017, the reference study that analyzes the life sciences and healthcare sector in Catalonia, on 5th December in Barcelona.

The event will be chaired by The Honorable Quim Torra, President of the Generalitat de Catalunya, and Mr. Jordi Naval, CEO of Biocat.

The meeting will include the keynote by Dr. Daria Tataj, chairwoman of the RISE High-Level Advisors to Carlos Moedas, European Commissioner for Research, Science and Innovation, and success stories of technology transfer in Catalonia:

Date: 5 December, 2018
Place: Auditorium Axa · Avinguda Diagonal, 547 · Barcelona

More information

Check the reference study of the BioRegion of Catalonia, a publication summarizing the situation and trends of the sector.

12 Nov

Oncothon 2018

Oncothon 2018

In the framework of the Onconet Sudoe European project, Oncothon will be a 2-day event that will bring the opportunity for professional from different areas such as oncology, bioinformatics, engineer or biomedical research, from academic and enterprise settings, to know how cancer genomics is opening new pathways for cancer diagnosis and treatment.

Attendees will have the opportunity to attend outstanding talks about how to exploit cancer genomics data and participate in collaborative sessions with interdisciplinary teams to collaborate and brainstorm about innovative solutions.

The institutional opening will be in charge of Angela Moca, Onconet Sudoe project coordinator (Université Toulouse III Paul Sabatier) and Lina Gálvez, regional minister of Knowledge, Research and University of Junta de Andalucía.

Goodgut has invited at the Cancer Interception Workshop on 12 November. Sara Ramió, Project Manager at GoodGut, will talk about The Microbiome and Cancer with Eduardo Pareja of Era7 Bioinformatics. GoodGut is developing RAID-CRC, a pioneering test non-invasive, fast, easy to use and economical to pre-diagnose colon cancer and determine the risk in previous stages, using biomarkers in stool samples.

This Oncothon arises in the framework of the Onconet Sudoe European project.

Date: 12-13 November, 2018
Place: Parque Tecnológico de Ciencias de la Salud de Granada

More information

 

26 Oct

Gebro Pharma and Goodgut unite to advance the treatment of Crohn’s disease

Gebro Pharma and Goodgut unite to advance the treatment of Crohn’s disease

Gebro Pharma and Goodgut have come together to explore, by means of a clinical trial, whether or not variations in the composition of intestinal flora influence patients’ response to treatment for inflammatory bowel disease (IBD) in order to define these bacterial markers as a parameter for predicting which patients will respond best.

It is estimated that IBD currently affects around 2.2 million people in Europe and approximately 120,000 in Spain, with the incidence of the disease rising globally. The existing treatments not only have a high cost and significant side effects, but are effective in only 60% of patients, of whom around 50% end up becoming non-responsive to the treatment.

Recent studies indicate that the bacterial communities present in the colon mucosa of a patient with Crohn’s disease, ulcerative colitis or irritable bowel syndrome (IBS) are structurally different from those of healthy individuals.

The University Hospital Doctor Josep Trueta in Girona is participating in the trial, led by Dr Xavier Aldeguer, Head of the Digestive Tract Department at the hospital, and Lecturer in Digestive Physiology at the University of Girona Faculty of Medicine. Other team members include Mariona Serra, Goodgut CEO and pharmacologist, and Bellvitge University Hospital, with the collaboration of Dr Jordi Guardiola, Head of its Digestive Tract Department.

The growing role of intestinal microbiota

In recent years the role of microbiota has gradually become clearer, and studies on the matter have become increasingly common due to the relevance and impact that resident bacteria in physiology and pathology have on human health.

The main functions of intestinal microbiota include metabolic activities, that is, the recovery of energy and nutrients, and protection of the individual against invasion by foreign micro-organisms. Intestinal bacteria also play an essential role in developing and modulating the immune system, meaning that alterations to the balance of these bacterial species have significant repercussions involving microflora in multiple pathological processes, not only in the gastrointestinal tract, as in IBD or colon cancer, but in the whole organism.

With bacterial flora having been described as an agent triggering the pathogenesis of IBD, the effectiveness of the treatment of said diseases could be subject to differences in its composition. In fact, around 30% of the patients do not respond to treatment have intestinal dysbiosis (imbalance or impoverishment); it appears that this factor means that a higher degree of dysbiosis means a lower response to the treatment.